Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm

Recruiting now

Conditions studied: Intracranial Neoplasm

In brief

This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.

Key facts

Study ID

NCT06474533

Run by

Thomas Hope

People needed

199

Starts

2024-06-21

Expected to finish

2028-08-31

Last updated by the study team

2026-04-03

Who can join

Age: 4 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Presence or suspicion of intracranial neoplasm in two populations:
• Population 1: Participants after primary treatment (radiation therapy and/or surgery) with suspicion of recurrence on MRI.
• Three sub-populations will be considered:
• Recurrent metastatic lesions.
• Recurrent high-grade gliomas (Grades 3 and 4).
• Recurrent low-grade gliomas (Grade 2).
• Population 2: Participants prior to primary treatment with planned biopsy or surgical resection.
• Age > 3 years.
• Participants in other clinical trials will be eligible for this study including patients undergoing surgery guided by 5-aminolevulinic acid.

You may not qualify if…

• Participants with known incompatibility to PET or Computerized tomography (CT)/magnetic resonance imaging (MRI) scans.
• Participants unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation.
• Sedation or anesthesia can be used for participants who cannot tolerate the exam.

Where it is running

• University of California, San Francisco — San Francisco, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.